Loading clinical trials...
Loading clinical trials...
Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy
Conditions
Interventions
Apalutamide
Leuprolide
+2 more
Locations
4
United States
University of California, San Diego Moores Cancer Center
La Jolla, California, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Start Date
October 19, 2016
Primary Completion Date
April 5, 2022
Completion Date
July 10, 2024
Last Updated
June 13, 2025
NCT07177937
NCT06844383
NCT06594926
NCT06926283
NCT06487507
NCT07004582
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions